1. Who is Investing in Biotech Today? Kris Jenner
Marina Bozilenko interviews Dr. Kris Jenner of T. Rowe Price. What is the mood this year at the J.P. Morgan Healthcare Conference? What business models are investors looking for nowadays? How is the tone cautiously optimistic? Who is investing in Biotech today? Are we looking at the “core 100″ or has the base expanded?
2. Reconsidering Small and Mid Caps, IPOs, and Value Drivers. Kris Jenner
Are small and mid-cap Biotech companies now being favored by investors? Many IPO have been filed; what will make T. Rowe buy? What will be driving the value of biotechnology stocks in 2010? An interview of Dr. Kris Jenner of T. Rowe Price, by Marina Bozilenko.
3. Shareholder Activism in 2010, Good or Bad? Kris Jenner
Will shareholder activism increase this year? How will that affect Biotech? What are your market predictions for 2010? An interview of Dr. Kris Jenner of T. Rowe Price, by Marina Bozilenko.
4. A Transformative Crisis, or Just Another Cycle? Ansbert Gadicke
Marina Bozilenko interviews Dr. Ansbert Gadicke of MPM Capital. What is different this year at the J.P. Morgan Healthcare Conference? Does it look like we just went through another cycle, or are we seeing transformative change in the industry? From the venture capital perspective, how can this change be characterized? Where are we seeing increased pressure? What are the VCs looking at in new investments?
5. Key Issues for Venture Capital Investments and Fund Raising. Ansbert Gadicke
Are the key issues for venture capitalists in the current market environment? prediction for new funds trying to raise K? effect on the community? How will it affect early stage technology? An interview of Dr. Ansbert Gadicke of MPM Capital, by Marina Bozilenko.
6. Pharma Opportunities, Novel Technologies, and Diseases of the Decade. Ansbert Gadicke
Will Pharma consolidation create attractive opportunities for Venture Capitalists? What will be the next decade in technology? Which disease therapies will define this coming decade? An interview of Dr. Ansbert Gadicke of MPM Capital, by Marina Bozilenko.
7. The Insider Perspective, with Geoff Meacham (Part 1)
Marina Bozilenko interviews Geoff Meacham, Senior Biotechnology Analyst at JP Morgan. What were the companies that gave the tone, and what was the major news that came out during the week? What are the major milestones that could make or break 2010 for biotech? Have the under-served small cap become a good opportunity?
8. The Insider Perspective, with Geoff Meacham (Part 2)
At the end of the 2010 JPM conf, what is the best company-profile for a successful IPO? Is it true that Pharma’s validation is no longer sought? Is there a new trend in business models for biotech? What is the take home message of the 2010 conference? An interview of Geoff Meacham of JP Morgan, by Marina Bozilenko.
This interview was conducted at the JP Morgan Conference, on January 11th, 12th, and 13th 2010, in San Francisco.
Featuring:
DISCLAIMER: VIEWERS SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK.
Related Videos: